Pfizer Laments Price Cut Needed To Secure Xalkori NICE Yes
Executive Summary
Pfizer warns that price cuts are unsustainable as UK HTA NICE gives provisional backing to Xalkori and Novartis' Afinitor. The drug makers had offered additional, undisclosed price cuts for their cancer therapies.
You may also be interested in...
Ibrance v Kisqali: Quicker Novartis Discount Helps Cut UK NICE’s Timeline
It took NICE, England’s health technology appraisal body, 84 days to say yes to Novartis’ Kisqali and almost a year to recommend Pfizer’s Ibrance. Willingness to sacrifice on price could have had a big impact on timelines.
Pfizer To Compromise On NICE Price For Ibrance?
NICE, the HTA for England and Wales, is poised to say no to Pfizer’s Ibrance (palbociclib), because the cost of the drug is too big in relation to its benefits. The company will likely have to come back with a patient access scheme to secure reimbursement.
NICE Backs Pfizer’s Xalkori In Lung Cancer After Firm Cuts Price (Again)
Pfizer’s oral therapy Xalkori (criotinib) for ALK-positive non-small cell lung cancer wins backing by the UK HTA after drug maker offers bigger discount than previously made and more supporting data.